CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
9-aminocamptothecindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00001427
NCT00001427Phase 2Completed
CompareCT.gov

A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With Advanced Ovarian Cancer Previously Treated With Paclitaxel and Cisplatin

National Cancer Institute (NCI)·interventional·Posted Dec 10, 2002·Updated Mar 4, 2008

In Brief

A Phase 2 clinical trial evaluating 9-aminocamptothecin for Ovarian Neoplasms. Completed, across 1 site.

Detailed Summary

The objectives of this study are to determine the response rate to 9-AC in patients with advanced ovarian cancer who have recurrent disease after paclitaxel- and cisplatin-based chemotherapy regimens.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 10, 2002
Enrollment StartJan 1, 1995
Study CompletionApr 1, 2000
TodayJul 2, 2026
Posted 23.6 years ago

Interventions

9-aminocamptothecindrug